You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

Fig. 3

Intravenous HER2 CAR T cells can effectively treat medulloblastoma, but requires a higher dose level. a Outline of experimental setup. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were given tumor and treated with human CAR T cells IV as shown, at one of two dose levels. Bioluminescent imaging was performed using a Xenogen IVIS apparatus twice per week. b Tumor growth curves for NSG mice treated with either HER2 and CD19 CAR T cells IV at both high and low dose levels on Day 0. Results are shown for two experiments using T cells from two separate donors. Error bars represent standard error of the mean. For shown statistics, linear regressions were fitted to each curve and slopes were compared using an ANOVA test. c Bioluminescent images from selected timepoints during the experiments. Indicated doses represent number of CAR positive T cells injected per mouse. d Brain and peripheral blood were harvested from mice on day 22 post- treatment and analyzed by flow cytometry. Total amounts of human CAR T cells in the brain and relative concentrations in the peripheral blood were measured and compared as previously described in Fig. 2

Back to article page